Jefferies Financial Group Inc. Acquires New Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Jefferies Financial Group Inc. acquired a new stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 165,000 shares of the company's stock, valued at approximately $4,868,000. Jefferies Financial Group Inc. owned 0.33% of Immunocore at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. bought a new stake in Immunocore in the 4th quarter valued at about $25,000. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC increased its position in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares in the last quarter. Tema Etfs LLC bought a new stake in Immunocore in the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC increased its holdings in Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after purchasing an additional 3,238 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Immunocore Stock Performance

Shares of IMCR stock traded up $1.45 during trading on Friday, hitting $36.49. The company's stock had a trading volume of 817,284 shares, compared to its average volume of 390,909. The company has a market cap of $1.83 billion, a PE ratio of -38.41 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The business has a fifty day moving average of $29.37 and a 200-day moving average of $30.00. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $49.05.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.49) earnings per share. As a group, research analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the company. Needham & Company LLC reissued a "buy" rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Oppenheimer boosted their price objective on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley reissued an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday. They set a "buy" rating and a $65.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.